{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:15:03Z","timestamp":1762521303375,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.3816\/cbc.2009.n.008","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T21:12:05Z","timestamp":1237497125000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration"],"prefix":"10.3816","volume":"9","author":[{"given":"Victor G.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongming","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayme","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Mershon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2009.n.008_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/BD-2006-24107","article-title":"Chemoprevention of breast cancer in postmenopausal women","volume":"24","author":"Geller","year":"2005","journal-title":"Breast Dis"},{"year":"2007","series-title":"Breast Cancer Facts & Figures","author":"American Cancer Society","key":"10.3816\/CBC.2009.n.008_bib2"},{"year":"1975","series-title":"SEER Cancer Statistics Review","key":"10.3816\/CBC.2009.n.008_bib3"},{"key":"10.3816\/CBC.2009.n.008_bib4","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","article-title":"Breast cancer","volume":"365","author":"Veronesi","year":"2005","journal-title":"Lancet"},{"year":"2003","series-title":"Nolvadex (tamoxifen citrate) [package insert]","key":"10.3816\/CBC.2009.n.008_bib5"},{"key":"10.3816\/CBC.2009.n.008_bib6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"year":"2007","series-title":"Evista (raloxifene HCl) [package insert]","key":"10.3816\/CBC.2009.n.008_bib7"},{"key":"10.3816\/CBC.2009.n.008_bib8","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published errata in: JAMA 2006; 296:2926 and JAMA 2007; 298:973]","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.3816\/CBC.2009.n.008_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breastcancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.008_bib10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.008_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.008_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.008_bib14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djk072","article-title":"Tamoxifen: an enduring star","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation [published erratum in: Breast Cancer Res Treat 2001; 67:191]","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.n.008_bib19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"New Engl J Med"},{"key":"10.3816\/CBC.2009.n.008_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.3816\/CBC.2009.n.008_bib22","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CBC.2009.n.008_bib23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.3816\/CBC.2009.n.008_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/sim.3549","article-title":"Propensity score estimation with missing values using multiple imputation missingness pattern (MIMP) approach","author":"Qu","year":"2009","journal-title":"Stat Med"},{"key":"10.3816\/CBC.2009.n.008_bib26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","article-title":"Validation studies for models projecting the risk of invasive and total breast cancer incidence","volume":"91","author":"Costantino","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib27","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2009.n.008_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1073\/pnas.0710887105","article-title":"Tamoxifen-stimulated growth of breast cancer due to p21 loss","volume":"105","author":"Abukhdeir","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CBC.2009.n.008_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jsbmb.2004.12.005","article-title":"Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy","volume":"93","author":"Osipo","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.3816\/CBC.2009.n.008_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(87)90717-3","article-title":"Clinical significance of tamoxifen withdrawal response","volume":"1","author":"Canney","year":"1987","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.008_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/oxfordjournals.annonc.a058286","article-title":"Response after withdrawal of tamoxifen and progestogens in advanced breast cancer","volume":"3","author":"Howell","year":"1992","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2009.n.008_bib32","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1081\/CNV-200032978","article-title":"Raloxifene rebound regression","volume":"22","author":"Dosik","year":"2004","journal-title":"Cancer Invest"},{"key":"10.3816\/CBC.2009.n.008_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.breast.2005.08.022","article-title":"The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy","volume":"14","author":"Jordan","year":"2005","journal-title":"Breast"},{"key":"10.3816\/CBC.2009.n.008_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-004-4776-0","article-title":"Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant","volume":"92","author":"Robertson","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.n.008_bib35","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CBC.2001.n.009","article-title":"Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view","volume":"2","author":"Costantino","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2009.n.008_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/95.2.160","article-title":"Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women","volume":"95","author":"Veronesi","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.008_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jnci\/95.2.91","article-title":"Preventing hormone-dependent breast cancer in high-risk women","volume":"95","author":"Vogel","year":"2003","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:19Z","timestamp":1761512959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911706425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1526820911706425"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2009.n.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2009.n.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}